Does N92.5 require prior authorization?

No, N92.5 does not require prior authorization (medium confidence). Covered without prior authorization by at least one policy, though another does not cover it.

Backwork Sign up free

`N92.5`, Other specified irregular menstruation

ICD-10-CM

Prior Authorization

No Prior Auth Required

Covered without prior authorization by at least one policy, though another does not cover it (medium confidence)

Documentation Required

Medical records for patients receiving a once‑yearly implant must document ongoing follow‑up visits at least every 3 to 4 months and must be provided upon request; lack of requested documentation will result in denial as not medically necessary.
Physician documentation supporting reasonable expectation of survival >12 months is required for coverage of once‑yearly implants for prostate cancer.
Billing frequency should match the drug formulation administered (e.g., bill Vantas 50 mg implant once per 12 months, Eligard 22.5 mg billed per its 3‑month formulation); medical record must support billed frequency when requested.
For surveillance: documentation of Lynch syndrome/genetic susceptibility to endometrial cancer (Z15.04) when endometrial surveillance is performed

Key Coverage Criteria

GnRH/LHRH analogs (leuprolide, goserelin, triptorelin, histrelin, leuprolide mesylate/Camcevi) are covered for FDA‑approved indications and for recognized off‑label uses that meet the criteria of LCD L33394.
Leuprolide acetate and histrelin implants administered every 12 months are covered for treatment of prostate cancer when the treating physician reasonably expects the patient to survive at least 12 months.
GnRH analogs are covered when administered at frequencies consistent with the specific product's labeled duration of action (e.g., monthly, every 3, 4, 6, or 12 months).
ICD-10 diagnoses listed as 'covered if selection criteria are met' (examples listed in policy): C54.1 - C54.9 (Malignant neoplasm of corpus uteri [except isthmus]); D06.0 - D07.0 (Carcinoma in situ of cervix uteri or other and unspecified parts of uterus); N85.00 - N85.02 (Endometrial hyperplasia); N92.1 (Excessive and frequent menstruation with irregular cycle); N92.4 (Excessive bleeding in the premenopausal period); N92.5, N93.8 (Other abnormal bleeding from female genital tract); N93.9 (Abnor [...]
Endometrial biopsy (sampling) for histological tissue examination in the diagnostic evaluation of abnormal uterine bleeding in women suspected of having endometrial hyperplasia or endometrial carcinoma
Endometrial biopsy (sampling) for endometrial cancer surveillance in women with Lynch syndrome

8 Active Policies

NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

A52453, Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

NGS-JK-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

AETNA-CPB-0769, Endometrial Cancer Screening, Diagnosis, and Prognosis

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about N92.5 Sign up free

N92.5, Other specified irregular menstruation